vs
Side-by-side financial comparison of Arbutus Biopharma Corp (ABUS) and CuriosityStream Inc. (CURI). Click either name above to swap in a different company.
CuriosityStream Inc. is the larger business by last-quarter revenue ($19.2M vs $10.7M, roughly 1.8× Arbutus Biopharma Corp). Arbutus Biopharma Corp runs the higher net margin — 23.5% vs -19.7%, a 43.2% gap on every dollar of revenue. On growth, Arbutus Biopharma Corp posted the faster year-over-year revenue change (522.2% vs 35.8%). Over the past eight quarters, CuriosityStream Inc.'s revenue compounded faster (26.5% CAGR vs -13.2%).
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
Curiosity Stream Inc., formerly branded as CuriosityStream, is an American media company and over-the-top subscription video streaming service which offers documentary programming including films, series, and TV shows. The company offers a video on demand subscription service branded as "Curiosity Stream" and a linear broadcast television channel known as the Curiosity Channel through various services including FuboTV and The Roku Channel.
ABUS vs CURI — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.7M | $19.2M |
| Net Profit | $2.5M | $-3.8M |
| Gross Margin | — | — |
| Operating Margin | 13.9% | -17.6% |
| Net Margin | 23.5% | -19.7% |
| Revenue YoY | 522.2% | 35.8% |
| Net Profit YoY | 112.7% | -34.6% |
| EPS (diluted) | $0.01 | $-0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $19.2M | ||
| Q3 25 | — | $18.4M | ||
| Q2 25 | $10.7M | $19.0M | ||
| Q1 25 | — | $15.1M | ||
| Q4 24 | — | $14.1M | ||
| Q3 24 | — | $12.6M | ||
| Q2 24 | — | $12.4M | ||
| Q1 24 | — | $12.0M |
| Q4 25 | — | $-3.8M | ||
| Q3 25 | — | $-3.7M | ||
| Q2 25 | $2.5M | $784.0K | ||
| Q1 25 | — | $319.0K | ||
| Q4 24 | — | $-2.8M | ||
| Q3 24 | — | $-3.1M | ||
| Q2 24 | — | $-2.0M | ||
| Q1 24 | — | $-5.0M |
| Q4 25 | — | -17.6% | ||
| Q3 25 | — | -24.5% | ||
| Q2 25 | 13.9% | 2.5% | ||
| Q1 25 | — | 0.5% | ||
| Q4 24 | — | -27.4% | ||
| Q3 24 | — | -25.8% | ||
| Q2 24 | — | -20.6% | ||
| Q1 24 | — | -30.4% |
| Q4 25 | — | -19.7% | ||
| Q3 25 | — | -20.4% | ||
| Q2 25 | 23.5% | 4.1% | ||
| Q1 25 | — | 2.1% | ||
| Q4 24 | — | -19.9% | ||
| Q3 24 | — | -24.3% | ||
| Q2 24 | — | -16.4% | ||
| Q1 24 | — | -42.0% |
| Q4 25 | — | $-0.07 | ||
| Q3 25 | — | $-0.06 | ||
| Q2 25 | $0.01 | $0.01 | ||
| Q1 25 | — | $0.01 | ||
| Q4 24 | — | $-0.05 | ||
| Q3 24 | — | $-0.06 | ||
| Q2 24 | — | $-0.04 | ||
| Q1 24 | — | $-0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.4M | $27.3M |
| Total DebtLower is stronger | $0 | — |
| Stockholders' EquityBook value | $83.0M | $41.5M |
| Total Assets | $103.3M | $75.7M |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $27.3M | ||
| Q3 25 | — | $27.8M | ||
| Q2 25 | $37.4M | $28.1M | ||
| Q1 25 | — | $33.4M | ||
| Q4 24 | — | $32.1M | ||
| Q3 24 | — | $33.2M | ||
| Q2 24 | — | $39.5M | ||
| Q1 24 | — | $38.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $0 | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $41.5M | ||
| Q3 25 | — | $47.2M | ||
| Q2 25 | $83.0M | $49.8M | ||
| Q1 25 | — | $58.1M | ||
| Q4 24 | — | $57.8M | ||
| Q3 24 | — | $62.2M | ||
| Q2 24 | — | $64.8M | ||
| Q1 24 | — | $67.0M |
| Q4 25 | — | $75.7M | ||
| Q3 25 | — | $74.7M | ||
| Q2 25 | $103.3M | $78.7M | ||
| Q1 25 | — | $85.3M | ||
| Q4 24 | — | $86.2M | ||
| Q3 24 | — | $87.6M | ||
| Q2 24 | — | $90.9M | ||
| Q1 24 | — | $94.6M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.7M | $4.0M |
| Free Cash FlowOCF − Capex | — | $3.9M |
| FCF MarginFCF / Revenue | — | 20.5% |
| Capex IntensityCapex / Revenue | 0.0% | 0.1% |
| Cash ConversionOCF / Net Profit | -6.24× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $4.0M | ||
| Q3 25 | — | $4.4M | ||
| Q2 25 | $-15.7M | $2.8M | ||
| Q1 25 | — | $1.9M | ||
| Q4 24 | — | $3.0M | ||
| Q3 24 | — | $2.3M | ||
| Q2 24 | — | $2.2M | ||
| Q1 24 | — | $666.0K |
| Q4 25 | — | $3.9M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $1.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 20.5% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 12.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 0.1% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | 0.0% | 0.0% | ||
| Q1 25 | — | 0.5% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -6.24× | 3.56× | ||
| Q1 25 | — | 6.03× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
